• Multiple Epitopes
• Numerous Target Combination & Backbones
• High-throughput In Vivo Screening
Platform highlights:
• High-throughput and rapid generation of BsADCs
• Huge potential for a large number of BsADCs targeting dual TAAs
• Improved translational efficiency through preclinical testing in large animals
• Target knock-out in RenLite mice increases the chance of obtaining novel binding epitopes and species cross- reactivity, resulting in more diverse products
• Conjugation of payload to naturally available amino acid side-chains (cysteine) is similar to mAbs.
